1. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, June 8, 2017 Subject(s): Antibodies, Monoclonal -- therapeutic useDermatitis, Atopic -- drug therapyInterleukin-4 Receptor alpha Subunit -- antagonists & inhibitorsPhosphodiesterase 4 Inhibitors -- therapeutic useAntibodies, Monoclonal -- adverse effectsCost-Benefit AnalysisCyclosporine -- therapeutic usePhosphodiesterase 4 Inhibitors -- adverse effectsPhototherapyRandomized Controlled Trials as TopicTreatment OutcomeHumansUnited States
2. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report Publication: Boston, MA : Institute for Clinical and Economic Review, December 2 2016 Subject(s): Comparative Effectiveness ResearchImmunologic Factors -- therapeutic usePsoriasis -- drug therapyAdalimumab -- therapeutic useBenchmarkingEtanercept -- therapeutic useImmunologic Factors -- adverse effectsImmunologic Factors -- economicsInterleukin-12 -- antagonists & inhibitorsInterleukin-17Interleukin-23 -- antagonists & inhibitorsPhosphodiesterase 4 InhibitorsPhototherapyPsoriasis -- immunologyPsoriasis -- therapyRandomized Controlled Trials as TopicSeverity of Illness IndexTumor Necrosis Factor-alpha -- antagonists & inhibitorsUstekinumab -- therapeutic useValue-Based PurchasingHumansUnited States
